ReOxy: Breathing Innovation for Heart Health

Heart disease remains the leading cause of death worldwide — but what if improving cardiovascular fitness didn’t require strenuous exercise?
A fascinating clinical study published in Clinical Cardiology explored exactly that. Researchers from Moscow’s Sechenov First State Medical University and Dublin City University investigated whether Intermittent Hypoxia–Hyperoxia Training (IHHT) using ReOxy technology could safely improve health and exercise tolerance in patients with coronary artery disease (CAD).

What is Intermittent Hypoxia–Hyperoxia Training (IHHT)?

IHHT involves alternating between breathing low-oxygen (hypoxic) and high-oxygen (hyperoxic) air through a specialised device — in this case, the ReOxy system by Ai Mediq (Luxembourg).
Unlike traditional exercise-based cardiac rehab, patients simply sit or recline while the ReOxy device adjusts oxygen levels to create controlled “stress” and “recovery” phases for the body. This pattern trains the cells to adapt — much like exercise — without physical strain.

The concept builds on decades of research into “hypoxic conditioning,” where short bursts of reduced oxygen exposure stimulate adaptive changes that support better metabolism, oxygen efficiency, and cardiovascular resilience.

The Study Design

Participants: 46 patients with stable coronary artery disease (NYHA class II–III).
Intervention: 27 patients completed 15 ReOxy IHHT sessions over three weeks (three sessions per week).
Control: 19 patients received sham sessions breathing normal air (21% O₂) after completing standard cardiac rehabilitation.
Oxygen levels: Hypoxia at 10–12% O₂, Hyperoxia at 30–35% O₂.
Monitoring: Continuous supervision by medical staff and fingertip pulse oximetry.

No exercise was required — patients simply breathed through the ReOxy device under clinical supervision.

Results: Significant Gains Without Exercise

After completing IHHT with ReOxy, patients showed:

✅ Improved exercise capacity – measurable increase in peak oxygen uptake (VO₂peak), a key indicator of cardiovascular fitness.
✅ Lower blood pressure – both systolic and diastolic pressures fell after treatment.
✅ Better heart efficiency – left ventricular ejection fraction increased, showing improved cardiac performance.
✅ Improved lipid profile – total cholesterol and LDL levels decreased.
✅ Lower blood glucose – fasting glucose dropped significantly at one-month follow-up.
✅ Enhanced quality of life – fewer angina episodes and better scores in the Seattle Angina Questionnaire across all measures (physical limitation, angina stability, frequency, treatment satisfaction, and disease perception).

No severe adverse effects were reported, confirming IHHT’s safety and tolerability.

How Does It Work?

The transition from low to high oxygen stimulates the body’s adaptive stress-response pathways — boosting mitochondrial function, antioxidant defence, and autonomic balance.
By mimicking the physiological challenges of exercise, ReOxy therapy enhances oxygen utilisation, improves vascular health, and promotes more efficient energy metabolism — all while the patient rests.

ReOxy vs Traditional Rehab

Interestingly, the study found that outcomes from IHHT using ReOxy were comparable to those of an eight-week standard cardiac rehabilitation program.
For patients unable to participate in physical rehab due to mobility limitations or joint issues, IHHT offers a powerful, non-invasive alternative.

The Takeaway

This landmark trial highlights how ReOxy-guided intermittent hypoxia–hyperoxia therapy can:

Strengthen cardiovascular health,
Improve metabolic markers,
Enhance overall quality of life,
And do so safely and comfortably, without exercise.

As the evidence grows, ReOxy IHHT stands at the forefront of adaptive medicine — offering a scientifically validated way to condition the body’s oxygen systems and support recovery in heart disease, chronic fatigue, metabolic syndrome, and beyond.

References:
Glazachev O.S. et al. (2017). Adaptations following an intermittent hypoxia-hyperoxia training in coronary artery disease patients: a controlled study. Clinical Cardiology, 40(5), 370–376. https://doi.org/10.1002/clc.22670

Adaptations following an interm…